No tumor remains of interest as Renal cell cancer, and the interest keeps swelling not only with the incidence of the disease, but with various discoveries in genes and pathways going awry in this disease, scientists working with Target therapy are increasingly embolden to try new staff in kidney disease. The SWOG trial of Tarceva in papillary Renal cancer is just one demonstration of our confidence in Target therapy. And believe me it works as predicted! Overall response of 11% was achieved, and a number of stable diseases yielding an overall control of papillary renal cell cancers in 64 % of patients. Basically nothing to sneeze at! But this reenforce the notion that papillary cancers (primary c-Met) have a strong VEGF dependency, and that it is here that Tensorilimus may be may work better while Sunitinib will serve better in those diseases where VEGF is a secondary expression such as an secondary amplification as a result of Von Hipple Landau primary activity!
Nonetheless, what really made the name of Internist Tumor to Renal cancers is its associated Cytokine release and no further dedicated and detailed investigation has been fully deployed. And the main reasons, wright or wrong, have been around the fact that no clear Cytokine adjuvant treatment has made a difference for our patients (to be continued).
No comments:
Post a Comment